---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-053527"
form_type: "8-K"
ticker: "RANI"
cik: "0001856725"
company_name: "Rani Therapeutics Holdings, Inc."
filed_at: "2024-05-06T23:59:59+00:00"
generated_at: "2026-06-02T22:26:38.047883+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Rani Therapeutics Q1 net loss $14.8M; cash $39.6M; RT-111 Phase 1 positive

## Summary
- Cash, cash equivalents and marketable securities: $39.6M at March 31, 2024 (down from $48.5M year-end 2023).
- Net loss $14.8M for Q1 2024 vs $16.8M same quarter 2023; includes $3.9M stock-based comp.
- R&D expense $7.6M (down $2.1M YoY) on lower compensation and third-party costs.
- RT-111 (oral anti-IL-12/23 antibody) Phase 1 achieved high bioavailability, well-tolerated, no serious AEs.
- Expects Phase 2 trial for RT-102 (osteoporosis) in 2024; RaniPill HC Phase 1 readiness H2 2024.

## SEC filing metadata
- accession: 0000950170-24-053527
- form_type: 8-K
- ticker: RANI
- cik: 0001856725
- company_name: Rani Therapeutics Holdings, Inc.
- filed_at: 2024-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1856725/000095017024053527/0000950170-24-053527-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1856725/000095017024053527/rani-20240506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-053527
- JSON: https://secwatch.observer/filing/0000950170-24-053527.json
- Plain text: https://secwatch.observer/filing/0000950170-24-053527.txt

## Key facts
- Earnings Releases
  Rani Therapeutics Holdings, Inc. reported the three months ended March 31, 2024 results: net income Net loss for the three months ended March 31, 2024 was $14.8 million.
  - Period: the three months ended March 31, 2024
  - Net income: Net loss for the three months ended March 31, 2024 was $14.8 million
  - Result: reported results
  source text: Rani Therapeutics Holdings, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the three months ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1856725/000095017024053527/0000950170-24-053527-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.